Article

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIs

2023-12-06

Abstract excerpt

<title>Abstract</title> <p><bold>INTRODUCTION: </bold>Lung cancer is one of the most common and deadly cancers worldwide. Immunotherapy has penetrated into various stages of non-small cell lung cancer diagnosis and treatment.Immunotherapy has become the standard treatment choice for first-line and second-line advanced lung cancer, significantly prolonging the adverse prognosis caused by EGFR resistance. There is...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f553f060-f986-505b-b008-1234eb6aea16
DOI: 10.21203/rs.3.rs-3480542/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIsDOI 10.21203/rs.3.rs-3480542/v1Read

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].Semantic proximity Read

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity Read

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.Semantic proximity Read

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.Semantic proximity Read

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.Semantic proximity Read

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read